转移灶导向治疗联合或不联合帕博利珠单抗治疗寡转移性透明细胞肾细胞癌:两项前瞻性单臂2期试验的汇总分析
该探索性队列汇总分析纳入两项前瞻性单臂2期试验的150例寡转移性透明细胞肾细胞癌患者,比较放疗为基础的转移灶导向治疗(MDT)联合免疫检查点抑制剂(MDT+ICI,30例)与单纯MDT(120例)的疗效与免疫学差异。中位随访34个月后,MDT+ICI组无进展生存期有延长趋势但未达统计学显著性(HR 0.57,95%CI 0.32-1.02,P=0.058),且MDT+ICI更常见激活CD8+ T细胞的即时系统诱导。
要点
- MDT+ICI组较单纯MDT组PFS有延长趋势但未达统计学显著(HR 0.57,95%CI 0.32-1.02,P=0.058)。
- 既往接受过系统治疗的患者中,MDT+ICI的PFS获益更明显(交互作用检验)。
- MDT+ICI更常见激活CD8+ T细胞(ICOS+)的即时系统诱导及功能较弱CD8+ T细胞亚群减少。
核心结论
- 在寡转移性ccRCC中,MDT联合维持性ICI较单纯MDT有改善临床结局的证据,PFS延长趋势未达统计学显著性。
- MDT+ICI激发的免疫调节信号与观察到的临床结局优势相一致。
研究设计与样本
- 探索性队列研究,汇总两项既往报道的前瞻性单臂2期试验:MDT+ICI(NCT02855203)与MDT(NCT03575611)。
- 共纳入150例寡转移性ccRCC患者,其中MDT+ICI组30例,MDT组120例。
- 主要目标为比较RECIST定义的无进展生存期(PFS),次要目标为比较外周免疫细胞群体。
主要发现
- MDT+ICI组较MDT组转移灶更多(中位3 vs 1)且更年轻(中位62 vs 66)。
- 中位随访34个月后,MDT+ICI较MDT的PFS延长趋势未达统计学显著性(HR 0.57,95%CI 0.32-1.02,P=0.058)。
- 交互作用检验显示既往接受系统治疗的患者中MDT+ICI的PFS获益更大。
- MDT+ICI后更常见激活CD8+ T细胞(ICOS+)的即时系统诱导,以及功能较弱CD8+ T细胞亚群的减少。
临床怎么用
- 对于寡转移性ccRCC,可考虑在MDT基础上联合维持性ICI以改善临床结局。
- 既往接受过系统治疗的患者可能从MDT+ICI中获益更明显。
局限性
- 为两项单臂试验的汇总探索性分析,非随机对照设计。
- 两组基线特征不均衡:MDT+ICI组转移灶更多且更年轻。
- MDT+ICI组样本量较小(30例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiotherapy-based metastasis-directed therapy (MDT) has emerged as a treatment strategy for oligometastatic clear cell renal cell carcinoma (ccRCC). However, optimal integration of MDT with immune checkpoint inhibition (ICI) is unclear, especially in light of the M1 no evidence of disease subgroup analysis of KEYNOTE-564. We undertook an exploratory cohort study of two previously reported trials evaluating either MDT+ICI (NCT02855203) or MDT (NCT03575611) for oligometastatic ccRCC. The objective was primarily to compare RECIST-defined progression-free survival (PFS) and secondarily to compare peripheral immune populations. Among the 150 patients included in the analysis (MDT+ICI: 30; MDT: 120), the MDT+ICI cohort had more metastases (median 3 vs 1) and was slightly younger (median 62 vs 66) than MDT. After a median follow-up time of 34 mo, there was evidence for longer PFS after MDT+ICI vs MDT that did not reach statistical significance (hazard ratio, 0.57; 95% confidence interval: 0.32-1.02; p = 0.058). Interaction testing demonstrated greater PFS benefit with MDT+ICI among patients with previous receipt of systemic therapy. Immediate systemic induction of activated CD8+ T cells (ICOS+) was more common after MDT+ICI, as were decreases in less functional CD8+ T cell subsets. Taken together, this study provides evidence that adding maintenance ICI to MDT improves clinical outcomes for patients with oligometastatic ccRCC. MDT+ICI-evoked immunomodulatory signals are promising and support the observed superiority in clinical outcomes. The A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs) trial (NCT06004336) has been initiated to test the hypotheses generated by the present study.
引用
- Sherry AD, To V, D'souza C, et al. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. Eur Urol. 2026. PMID: 42049596. doi:10.1016/j.eururo.2026.03.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。